<DOC>
	<DOCNO>NCT02555813</DOCNO>
	<brief_summary>This observational program collect data tolerability , safety efficacy regard use Abraxane metastatic pancreatic cancer patient daily clinical routine . Additionally data dosage actually use patient collect . Patients pancreatic cancer additional disease document study , . Collected data might generate learning optimal use Abraxane daily routine setting .</brief_summary>
	<brief_title>Treatment Pancreatic Cancer With Abraxane</brief_title>
	<detailed_description>This observational program aim gain tolerability , safety efficacy data routine use Abraxane label indication metastatic pancreatic cancer . Additionally data real life dose daily clinical routine analyze . A detailed record medical history include co-morbidities pre-treatment regimen allow analysis impact thereof tolerability , dosage efficacy . Hands-on experience nab-paclitaxel limited Austria non-interventional study could enhance knowledge optimal drug handle Adverse Event management .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Metastatic pancreatic carcinoma 2 . Age &gt; 18 year 3 . Signed Informed Consent 4 . Normal hepatic , renal Bone Marrow function 1 . Pregnant lactating female 2 . Previous treatment metastatic pancreatic disease 3 . Known hypersensitivity nabpaclitaxel 4 . Neutrophils &lt; 1,5 x 10^9/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Metastatic Pancreatic Cancer</keyword>
	<keyword>nab-Paclitaxel</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Non-interventional</keyword>
</DOC>